Is vonoprazan safer than PPI? An In-depth Look at Potassium-Competitive Acid Blockers vs. Proton Pump Inhibitors
•
4 min read
In recent clinical trials for *H. pylori* eradication, vonoprazan-based triple therapy showed a significantly lower incidence of adverse events compared to PPI-based therapy. But is vonoprazan safer than PPIs overall, especially for long-term use? This comparison of pharmacologic action and reported side effects reveals key differences and considerations for patient safety.
